Results 1 to 10 of about 118 (86)
Frontiers in Medicine, 2022 Symptomatic vitreomacular adhesion (sVMA) impedes visual acuity and quality. Ocriplasmin is a recombinant protease, which may be injected into the vitreous cavity to treat this condition, yet controversy remains with respect to its effectiveness and ...
Yanling Wang, Ran You
exaly +3 more sources
Journal of Ophthalmic and Vision Research, 2021 Purpose: To assess the effect of patient baseline characteristics on the efficacy of ocriplasmin treatment for symptomatic vitreomacular adhesion (VMA) with full-thickness macular hole (FTMH) from phase 3/4 studies.
Brian C Joondeph +2 more
exaly +2 more sources
Incomplete Vitreomacular Traction Release Using Intravitreal Ocriplasmin
Case Reports in Ophthalmology, 2014 Purpose: To report the clinical course of our first 7 consecutive patients treated with intravitreal ocriplasmin (Jetrea®). Methods: Retrospective case series of the first 7 patients treated with ocriplasmin between January and December 2013 at an ...
Elliott H Sohn +2 more
exaly +3 more sources
Pharmacokinetics of Ocriplasmin in Vitreous
Investigative Ophthalmology and Visual Science, 2012 Ocriplasmin contains the active moiety of plasmin enzyme. At a physiologic pH, ocriplasmin is highly proteolytic and autolytic, limiting its duration of activity. Specific inhibitors of plasmin are present in the vitreous under normal and disease conditions and could affect its activity.
Marc D de Smet, Peter Stalmans
exaly +3 more sources
Assessment of E. coli Expression System for Overexpression of Active Recombinant Ocriplasmin [PDF]
Advanced Pharmaceutical Bulletin, 2021 Purpose: Ocriplasmin (Jetrea TM) is a FDA approved recombinant enzyme utilized in the treatment of vitreomacular adhesion (VMA). This is a recombinant C-terminal fragment of human plasmin produced using yeast Pichia pastoris.
Roghayyeh Baghban +5 more
doaj +1 more source
Engineering of Ocriplasmin Variants by Bioinformatics Methods for the Reduction of Proteolytic and Autolytic Activities [PDF]
Iranian Journal of Medical Sciences, 2021 Background: Ocriplasmin has been developed for the induction of posterior vitreous detachment in patients with vitreomacular adhesion. At physiological pH, ocriplasmin is susceptible to autolytic and proteolytic degradation, limiting its activity ...
Roghayyeh Baghban +7 more
doaj +1 more source
International Journal of Retina and Vitreous, 2023 Background We conducted a systematic review to compare the effects of pneumatic vitreolysis (PV), enzymatic vitreolysis (EVL) with ocriplasmin, and pars plana vitrectomy (PPV) on vitreomacular traction (VMT) syndrome and macular holes (MHs) to assess ...
Miguel A. Quiroz-Reyes +3 more
doaj +1 more source
Myopic macular hole detachment associated with intravitreal ocriplasmin
American Journal of Ophthalmology Case Reports, 2020 Purpose: To describe a case of macular hole retinal detachment in a high myope following intravitreal ocriplasmin injection. Observations: A 71-year-old highly myopic (−18.63 Dioptres) female received 125 μg of intravitreal ocriplasmin (Jetrea, Oxurion ...
Li Yen Goh +2 more
doaj +1 more source
BMJ Open Ophthalmology, 2021 Background/aims OASIS is a Phase IIIb trial (NCT01429441) assessing long-term outcomes in subjects with symptomatic vitreomacular adhesion (VMA). The purpose of this study is to report on the frequency, severity, location and time course of ellipsoid ...
Michael S Ip +4 more
doaj +1 more source
Senses and Sciences, 2016 Purpose: To evaluate the efficacy and the safety of the enzymatic vitreolysis with a single intravitreal injection of ocriplasmin 125 μg across a group of patients with symptomatic vitreomacular adhesion (sVMA) during 6 months follow up.
Fernanda Pacella +6 more
doaj +1 more source